Cancer Center conducts a clinical trial of Chemotherapy-related Cognitive Impairment and Acute Leukemia

Photo by Georg Arthur Pflueger

UNC Lineberger Comprehensive Cancer Center is recruiting patients for the clinical trial of Chemotherapy-related Cognitive Impairment and Acute Leukemia.

The study objective is to observe patient-reported and researcher-assessed cognitive function in adults with acute myeloid leukemia with chemotherapy treatment. The researchers will assess cognitive function using a battery of neuropsychological assessments, patient-reported questionnaire, and semi-structured interviews among participants in both control and intervention groups. The group assignment will be conducted through parent study (NCT04570709). Participating in this study will not affect participants' group assignment.

Among primary outcome measures are cognitive function as assessed by Functional Assessment of Cancer Therapy; processing speed and executive function as assessed by Trial Making Test; memory and verbal learning as assessed by Hopkins Verbal Learning Test-revised (HVLT-R); Speeded lexical fluency as assessed by Delis-Kaplan Executive Function System (D-KEFS) letter fluency; Attention and working memory as assessed by Wechsler Adult Intelligence Scale (WAIS)-digit span and Cognitive effort as assessed by Borg CR 10.

The population that can be enrolled into this study includes the patients with at the age of 60 years of age or more, with diagnosis of AML, who will receive HMA or low-dose cytarabine + VEN induction chemotherapy and have caregiver(s) willing to participate. They also participate in the parent study (PACT study, NCT04570709).

The location of the clinical trials: University of North Carolina Lineberger Comprehenisive Cancer Center, Chapel Hill, North Carolina, United States, 27599.

American Cancer Society, Inc. is collaborator in this study.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04644419